The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
These findings follow positive Phase 3 results presented earlier this year
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
First and only PARP inhibitor to improve overall survival in early breast cancer
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated
